Taconic launches preconditioned NASH mice to accelerate clinical development

By Vassia Barba

- Last updated on GMT

(Image: Getty/Adam Gault)
(Image: Getty/Adam Gault)

Related tags Mouse models models Liver disease Liver

Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.

Taconic Biosciences, a New York, US-based company developing animal models for clinical research announced the commercialization of a rodent model, preconditioned with diet-induced nonalcoholic steatohepatitis (NASH).

According to the company, there is increased demand for preconditioned models, since some of the available models require up to 26 weeks to become ready for study, causing time delays for drug discovery.

Additionally, the current absence of a commercial product forces researchers to use their vivarium space to condition animals for months, displacing other projects.

Michael Seiler, vice president of Taconic's commercial model portfolio, commented that the model launch will save time for researchers. Previously, they had to “plan studies months in advance and [were left with] little flexibility as new compounds were discovered along the way.”

NASH is a subtype of nonalcoholic fatty liver disease NAFLD. According to the National Institute of Diabetes and Digestive and Kidney Diseases​, NAFLD affects 30-40% of adults in the US while 3-12% of the same population have NASH, which can lead to liver failure or liver cancer.

Taconic has been further investing in its growth since the private equity (PE) firm H.I.G. Capital acquired​ the majority of its shares earlier this year.

The company recently also launched TruBiome​, a platform enabling the development of models with customized microbiota profiles, got its Wild Mouse licensed​ by the National Institutes of Health and sent a mouse​ to the International Space Station.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers